New and Emerging Therapies for Agitation Associated with Dementia Due to Alzheimer’s Disease (AD) is organized by Pri-Med.
Release Date: 07/14/2023
Expiration Date: 07/14/2024
Description:
Agitation is among the most common behavioral symptoms in patients with dementia, including Alzheimer’s dementia. It exacts a significant burden on patients because it is associated with not only greater morbidity and mortality, but also a faster cognitive and functional decline. This activity reviews pharmacological treatment options, both a newly approved agent that is the first ever to be indicated specifically for the treatment of agitation associated with dementia due to Alzheimer’s disease and also an array of agents in development.
Learning Objectives:
• Review efficacy and safety data for the first therapy approved for agitation associated with dementia due to Alzheimer’s disease
• Discuss the mechanism of action and available efficacy and safety data for emerging therapies for agitation associated with dementia due to Alzheimer’s disease